Trademark: 79371640
Word
GENOMIGON
Status
Pending
Status Code
645
Status Date
Tuesday, June 11, 2024
Serial Number
79371640
Mark Type
3
Filing Date
Monday, February 6, 2023

Trademark Owner History

Classifications
5 Pharmaceutical preparations and substances for the treatment of, e.g., malignant tumor diseases and malignant and benign blood diseases, infectious diseases; diagnostic preparations and materials for medical purposes; diagnostic substances for medical use; diagnostic testing materials for medical use, namely, medical diagnostic test media in the form of, e.g., strips, threads, liquids, gels, serums, for measuring, e.g., biomarkers in malignant diseases and hereditary diseases on a genetic basis or protein basis, gene variants in hereditary diseases and malignant diseases; medical diagnostic test strips for e.g., blood analysis, urine analysis, saliva analysis; biotechnological preparations for medical use in the nature of, e.g., pharmaceutical preparations for the treatment of cancer, malignant and non-malignant blood diseases and hereditary diseases; medicine, namely, cytostatics, antibodies, antibody-drug conjugates, therapeutically modified lymphocytes, hormone preparations, preparations for the targeted treatment of malignant and non-malignant diseases; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for the treatment of, e.g., malignant blood diseases, benign blood diseases, malignant solid tumors, benign solid tumors, cancer and hereditary diseases; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for healing or alleviating ailments and reducing symptoms); biological preparations for medical purposes, namely, biological preparations for the treatment of, e.g., malignant blood diseases, benign blood diseases, malignant solid tumors, benign solid tumors; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine
44 Medical services; medical analysis services relating to disease management, disease diagnosis services, disease prognosis; medical laboratory services for the analysis of samples taken from patients; health screening services in the field of, e.g., malignant tumor diseases, benign tumor diseases, malignant blood diseases, benign blood diseases, hereditary diseases, coagulation disorders; providing medical information in the healthcare sector; medical consultations; arranging of medical treatment in the field of, e.g., oncology, hematology, genetics, gene therapies, targeted therapy, cell therapies; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine
10 Genetic testing apparatus for medical purposes; diagnostic equipment and instruments for medical purposes for, e.g., the analysis of body fluids, tissue and blood (benign and malignant), protein structures of tumors, genetic code of tissue and blood cells, analysis of blood cells, blood plasma and blood serum; medical apparatus for carrying-out diagnostic tests for medical purposes for, e.g., cancer cells, leukemia cells, benign and malignant cells of humans and animals, genetic material; medical testing instruments for medical diagnostic purposes for, e.g., blood sugar levels, cancer cells, genetic material; electromedical diagnostic instruments, namely, electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; radiation instruments, for medical purposes, namely, radiation therapy devices; medical radiation apparatus for medical purposes; medical apparatus for the treatment of cancer; apparatus for DNA and RNA testing for medical purposes; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine
42 Scientific analysis in the field of, e.g., pharmaceuticals, medical devices; scientific research in the field of, e.g., genetics, hematology, oncology; genetic scientific research; pharmaceutical research services; clinical research in the field of, e.g., radiology, radiotherapy, surgical medicine, oncological system therapy of malignant and benign diseases, infectious diseases; research relating to biotechnology; medical research; computer aided diagnostic testing services, namely, diagnostic services for others for scientific research purposes; design and development of medical diagnostic apparatus; design and development of medical technology; development of pharmaceutical preparations and medicines; provision of information and data relating to medical and veterinary research and development; consultancy relating to research and development in the field of therapeutics; providing scientific research information in the field of medical disorders and their treatment; laboratory testing and analysis for medical research purposes in the field of, e.g., bacteriology, chemistry, life science, molecular genetics, protein diagnostics, oncology, hematology, radiology, radiotherapy; biomedical assay services and development for, e.g., the analysis of body fluids, tissue samples and fluids/blood and blood products for benign and malignant diseases in the field of diagnostic preparations, implements and medication; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine
The mark consists of the stylized wording "GENOMIGON" in blue. On the left side of the wording are twelve orange dots lined up to form a stylized orange helix. White represents background and/or transparent areas and is not claimed as a feature of the mark.
The color(s) orange and blue is/are claimed as a feature of the mark.

Trademark Events
Jun 12, 2023
New Application Office Supplied Data Entered
Jun 8, 2023
Sn Assigned For Sect 66a Appl From Ib
Jun 16, 2023
Application Filing Receipt Mailed
Nov 13, 2023
Non-Final Action Written
Nov 14, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Nov 15, 2023
Refusal Processed By Mpu
Nov 15, 2023
Non-Final Action Mailed - Refusal Sent To Ib
May 7, 2024
Correspondence Received In Law Office
May 7, 2024
Teas/Email Correspondence Entered
May 7, 2024
Teas Response To Office Action Received
Jun 11, 2024
Final Refusal Written
Jun 11, 2024
Notification Of Final Refusal Emailed
Jun 11, 2024
Final Refusal E-Mailed
Dec 4, 2023
Refusal Processed By Ib
Nov 3, 2023
Assigned To Examiner

Trademark Alertz updated from USPTO on 2030-01-24